keyword
MENU ▼
Read by QxMD icon Read
search

Lilly Oncology

keyword
https://www.readbyqxmd.com/read/29451078/oncologists-perceptions-of-drug-affordability-using-nccn-evidence-blocks-results-from-a-national-survey
#1
Bijal Shah-Manek, William Wong, Arliene Ravelo, Marco DiBonaventura
BACKGROUND: The increasing prevalence of cancer coupled with approvals of new drugs and technologies used in therapy have brought increased scrutiny to the cost and value of treatments in oncology. To address the rising concern about oncology drug costs, several organizations have developed value frameworks to help assess the value of oncology regimens. The objective of this study was to assess oncologists' perceptions, awareness, and knowledge of all oncology value frameworks in the United States and to understand oncologists' perceptions of affordability in the context of National Comprehensive Cancer Network (NCCN) Evidence Blocks...
February 16, 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29383980/optimizing-anti-vegf-treatment-outcomes-for-patients-with-neovascular-age-related-macular-degeneration
#2
Charles C Wykoff, W Lloyd Clark, Jared S Nielsen, Joel V Brill, Laurence S Greene, Cherilyn L Heggen
BACKGROUND: The introduction of anti-vascular endothelial growth factor (anti-VEGF) drugs to ophthalmology has revolutionized the treatment of neovascular age-related macular degeneration (nAMD). Despite this significant progress, gaps and challenges persist in the diagnosis of nAMD, initiation of treatment, and management of frequent intravitreal injections. Thus, nAMD remains a leading cause of blindness in the United States. OBJECTIVE: To present current knowledge, evidence, and expert perspectives on anti-VEGF therapies in nAMD to support managed care professionals and providers in decision making and collaborative strategies to overcome barriers to optimize anti-VEGF treatment outcomes among nAMD patients...
February 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29216806/an-industry-update-the-latest-developments-in-therapeutic-delivery
#3
Iain Simpson
This industry update covers the period from 1 September through 30 September 2017, and is based on information sourced from company press releases, scientific literature, patents and various news websites. The month saw the US FDA approve three new molecular entities, Aliqopa (copanlisib dihydrochloride) (Bayer Healthcare); Solosec (secnidazole) (Symbiomix Therapeutics) and Verzenio (abemaciclib) (Eli Lilly and Co). Intarcia Therapeutics Inc. has its application for approval of a novel drug device combination of exenatide for the treatment of diabetes rejected by FDA but said that it will work to address the concerns and refile the application...
January 2018: Therapeutic Delivery
https://www.readbyqxmd.com/read/29105670/-application-of-a-shared-interdisciplinary-and-multiprofessional-cardio-oncology-in-hospital-pathway
#4
Maria Laura Canale, Andrea Camerini, Massimo Magnacca, Jacopo Del Meglio, Alessio Lilli, Sara Donati, Lucia Belli, Stefania Lencioni, Domenico Amoroso, Giancarlo Casolo
The burden of cardiac side effects in oncology patients will dramatically increase in the near future as a result of the widespread use of anticancer agents affecting the cardiovascular system, the general population aging, the heightened attention in the detection of cardiac toxicity and the absolute gain in terms of overall survival. The relationship between cardiologists and oncologists should therefore be closer leading to the definition of cardio-oncology. The increased number of such patients requires the creation of a dedicated patient assistance program in order to guarantee every patient the possibility of an interdisciplinary and multiprofessional approach...
November 2017: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/29081023/combined-treatment-with-pemetrexed-and-vinflunine-in-patients-with-metastatic-urothelial-cell-carcinoma-after-prior-platinum-containing-chemotherapy-results-of-an-exploratory-phase-i-study
#5
H Pappot, H von der Maase, A Ullén, M Agerbæk
Vinflunine is to date the only registered agent for second-line treatment of metastatic urothelial cell carcinoma (UCC) in Europe. However, the effect is modest. Pemetrexed has demonstrated some single-agent activity in this disease entity. In order to improve treatment possibilities for UCC patients, a phase I trial (VINTREX) was undertaken to assess the safety of vinflunine and pemetrexed in metastatic UCC patients. A dose escalation design was planned to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of a vinflunine/pemetrexed combination...
October 28, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28836917/multiple-group-confirmatory-factor-analysis-of-the-dass-21-depression-and-anxiety-scales-how-do-they-perform-in-a-cancer-sample
#6
Rina S Fox, Teresa A Lillis, James Gerhart, Michael Hoerger, Paul Duberstein
The DASS-21 is a public domain instrument that is commonly used to evaluate depression and anxiety in psychiatric and community populations; however, the factor structure of the measure has not previously been examined in oncologic settings. Given that the psychometric properties of measures of distress may be compromised in the context of symptoms related to cancer and its treatment, the present study evaluated the psychometric properties of the DASS-21 Depression and Anxiety scales in cancer patients ( n = 376) as compared to noncancer control participants ( n = 207)...
January 1, 2017: Psychological Reports
https://www.readbyqxmd.com/read/28545495/the-impact-of-human-adipose-tissue-derived-stem-cells-on-breast-cancer-cells-implications-for-cell-assisted-lipotransfers-in-breast-reconstruction
#7
Eva Koellensperger, Lilly-Claire Bonnert, Inka Zoernig, Frederik Marmé, Stefanie Sandmann, Günter Germann, Felix Gramley, Uwe Leimer
BACKGROUND: In this study we evaluated the interactions of human adipose tissue-derived stem cells (ADSCs) and different human breast cancer cell lines (BRCAs) with regard to the safety of cell-assisted lipotransfers for breast reconstruction and a thereby unintended co-localization of ADSCs and BRCAs. METHODS: ADSCs were co-cultured with five different human BRCAs (MCF-7, MDA-MB-231, SK-BR-3, ZR-75-30, and EVSA-T) and primary BRCAs from one patient in a transwell system, and cell-cell-interactions were analyzed by assessing doubling time, migration and invasion, angiogenesis, quantitative real-time polymerase chain reaction (PCR) of more than 300 tumor-associated genes, and multiplex protein assays of 20 chemokines and growth factors and eight matrix metalloproteinases (MMPs)...
May 25, 2017: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/28479233/addition-of-gemcitabine-to-paclitaxel-epirubicin-and-cyclophosphamide-adjuvant-chemotherapy-for-women-with-early-stage-breast-cancer-tango-final-10-year-follow-up-of-an-open-label-randomised-phase-3-trial
#8
RANDOMIZED CONTROLLED TRIAL
Helena M Earl, Louise Hiller, Helen C Howard, Janet A Dunn, Jennie Young, Sarah J Bowden, Michelle McDermaid, Anna K Waterhouse, Gregory Wilson, Rajiv Agrawal, Susan O'Reilly, Angela Bowman, Diana M Ritchie, Andrew Goodman, Tamas Hickish, Karen McAdam, David Cameron, David Dodwell, Daniel W Rea, Carlos Caldas, Elena Provenzano, Jean E Abraham, Peter Canney, John P Crown, M John Kennedy, Robert Coleman, Robert C Leonard, James A Carmichael, Andrew M Wardley, Christopher J Poole
BACKGROUND: The tAnGo trial was designed to investigate the potential role of gemcitabine when added to anthracycline and taxane-containing adjuvant chemotherapy for early breast cancer. When this study was developed, gemcitabine had shown significant activity in metastatic breast cancer, and there was evidence of a favourable interaction with paclitaxel. METHODS: tAnGo was an international, open-label, randomised, phase 3 superiority trial that enrolled women aged 18 years or older with newly diagnosed, early-stage breast cancer who had a definite indication for chemotherapy, any nodal status, any hormone receptor status, Eastern Cooperative Oncology Group performance status of 0-1, and adequate bone marrow, hepatic, and renal function...
June 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28448782/amcp-partnership-forum-driving-value-and-outcomes-in-oncology
#9
(no author information available yet)
Innovation in cancer treatment has provided a wealth of recently available therapeutic agents and a healthy drug pipeline that promises to change the way we approach this disease and the lives of those affected in the years to come. However, the majority of these new agents, many of which are targeted to specific genomic features of various tumors, may challenge the health care system's ability to afford cancer care. This innovation drives the need to focus on the value of the treatments provided to patients with cancer and on methods to optimize the efficiency of the dollars we spend, in addition to the clinical value itself...
May 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28156474/a-consolidated-screening-tool-for-supportive-oncology-needs-and-distress
#10
Lauren Allison Wiebe, Shelly S Lo, Catherine Deamant, Betty Roggenkamp, Urjeet Patel, Pam Khosla, Patricia A Robinson, Frank J Penedo, James Gerhart, Teresa Lillis, William Dale, Ana Gordon, Rajul Kothari, Rosa Berardi, Julia Rachel Trosman, Christine B Weldon
72 Background: The IOM 2013 Report recommends that supportive oncology care start at cancer diagnosis; the Commission on Cancer (CoC) standard 3.2 requires distress screening and indicated action. Screening tools are not standardized across institutions and often address only a portion of patients' supportive oncology needs. METHODS: A collaborative of 100+ clinicians, funded by The Coleman Foundation, developed a patient-centric consolidated screening tool based on validated instruments (NCCN Distress Problem List, PHQ-4, PROMIS) and IOM and CoC...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28045649/cost-effectiveness-of-pemetrexed-in-combination-with-cisplatin-as-first-line-treatment-for-patients-with-advanced-non-squamous-non-small-cell-lung-cancer-in-spain
#11
Jonathan González García, Fernando Gutiérrez Nicolás, Gloria Julia Nazco Casariego, Cristina Valcárcel Nazco, Jose Norberto Batista López, Juana Oramas Rodríguez
INTRODUCTION: Lung cancer is the third most frequent neoplastic tumour in Spain, with around 27 000 new cases diagnosed per year; 80-95% of these are non-small-cell cancer (NSCLC), and the majority of cases are diagnosed in advanced stages of the disease, and for this reason it is one of the oncologic conditions with higher mortality rates (21.4% mean survival at 5 years). The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev)...
January 1, 2017: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/27718158/perceptions-of-oncologists-healthcare-policy-makers-patients-and-the-general-population-on-the-value-of-pharmaceutical-treatments-in-oncology
#12
José A Sacristán, Luís Lizan, Marta Comellas, Pilar Garrido, Cristina Avendaño, Juan J Cruz-Hernández, Javier Espinosa, Tatiana Dilla
INTRODUCTION: The purpose of this study was to explore the main factors explaining the relative weight of the different attributes that determine the value of oncologic treatments from the different perspectives of healthcare policy makers (HCPM), oncologists, patients and the general population in Spain. METHODS: Structured interviews were conducted to assess: (1) the importance of the attributes on treatment choice when comparing a new cancer drug with a standard cancer treatment; (2) the importance of survival, quality of life (QoL), costs and innovation in cancer; and (3) the most worrying side effects related to cancer drugs...
November 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27291997/olaratumab-and-doxorubicin-versus-doxorubicin-alone-for-treatment-of-soft-tissue-sarcoma-an-open-label-phase-1b-and-randomised-phase-2-trial
#13
RANDOMIZED CONTROLLED TRIAL
William D Tap, Robin L Jones, Brian A Van Tine, Bartosz Chmielowski, Anthony D Elias, Douglas Adkins, Mark Agulnik, Matthew M Cooney, Michael B Livingston, Gregory Pennock, Meera R Hameed, Gaurav D Shah, Amy Qin, Ashwin Shahir, Damien M Cronier, Robert Ilaria, Ilaria Conti, Jan Cosaert, Gary K Schwartz
BACKGROUND: Treatment with doxorubicin is a present standard of care for patients with metastatic soft-tissue sarcoma and median overall survival for those treated is 12-16 months, but few, if any, novel treatments or chemotherapy combinations have been able to improve these poor outcomes. Olaratumab is a human antiplatelet-derived growth factor receptor α monoclonal antibody that has antitumour activity in human sarcoma xenografts. We aimed to assess the efficacy of olaratumab plus doxorubicin in patients with advanced or metastatic soft-tissue sarcoma...
July 30, 2016: Lancet
https://www.readbyqxmd.com/read/27036177/patient-physician-discussions-about-costs-definitions-and-impact-on-cost-conversation-incidence-estimates
#14
Wynn G Hunter, Ashley Hesson, J Kelly Davis, Christine Kirby, Lillie D Williamson, Jamison A Barnett, Peter A Ubel
BACKGROUND: Nearly one in three Americans are financially burdened by their medical expenses. To mitigate financial distress, experts recommend routine physician-patient cost conversations. However, the content and incidence of these conversations are unclear, and rigorous definitions are lacking. We sought to develop a novel set of cost conversation definitions, and determine the impact of definitional variation on cost conversation incidence in three clinical settings. METHODS: Retrospective, mixed-methods analysis of transcribed dialogue from 1,755 outpatient encounters for routine clinical management of breast cancer, rheumatoid arthritis, and depression, occurring between 2010-2014...
March 31, 2016: BMC Health Services Research
https://www.readbyqxmd.com/read/26785714/what-strategies-do-physicians-and-patients-discuss-to-reduce-out-of-pocket-costs-analysis-of-cost-saving-strategies-in-1-755-outpatient-clinic-visits
#15
Wynn G Hunter, Cecilia Z Zhang, Ashley Hesson, J Kelly Davis, Christine Kirby, Lillie D Williamson, Jamison A Barnett, Peter A Ubel
BACKGROUND: More than 1 in 4 Americans report difficulty paying medical bills. Cost-reducing strategies discussed during outpatient physician visits remain poorly characterized. OBJECTIVE: We sought to determine how often patients and physicians discuss health care costs during outpatient visits and what strategies, if any, they discussed to lower patient out-of-pocket costs. DESIGN: Retrospective analysis of dialogue from 1,755 outpatient visits in community-based practices nationwide from 2010 to 2014...
October 2016: Medical Decision Making: An International Journal of the Society for Medical Decision Making
https://www.readbyqxmd.com/read/26272770/neoadjuvant-plus-adjuvant-bevacizumab-in-early-breast-cancer-nsabp-b-40-nrg-oncology-secondary-outcomes-of-a-phase-3-randomised-controlled-trial
#16
RANDOMIZED CONTROLLED TRIAL
Harry D Bear, Gong Tang, Priya Rastogi, Charles E Geyer, Qing Liu, André Robidoux, Luis Baez-Diaz, Adam M Brufsky, Rita S Mehta, Louis Fehrenbacher, James A Young, Francis M Senecal, Rakesh Gaur, Richard G Margolese, Paul T Adams, Howard M Gross, Joseph P Costantino, Soonmyung Paik, Sandra M Swain, Eleftherios P Mamounas, Norman Wolmark
BACKGROUND: NSABP B-40 was a 3 × 2 factorial trial testing whether adding capecitabine or gemcitabine to docetaxel followed by doxorubicin plus cyclophosphamide neoadjuvant chemotherapy would improve outcomes in women with operable, HER2-negative breast cancer and whether adding neoadjuvant plus adjuvant bevacizumab to neoadjuvant chemotherapy regimens would also improve outcomes. As reported previously, addition of neoadjuvant bevacizumab increased the proportion of patients achieving a pathological complete response, which was the primary endpoint...
September 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26127527/su-e-j-134-optimizing-technical-parameters-for-using-atlas-based-automatic-segmentation-for-evaluation-of-contour-accuracy-experience-with-cardiac-structures-from-nrg-oncology-rtog-0617
#17
J Yu, Y Gong, V Bar-Ad, T Giaddui, C Hu, E Gore, M Wheatley, J Witt, C Robinson, F Kong, J Bradley, J Galvin, Y Xiao
PURPOSE: Accurate contour delineation is crucial for radiotherapy. Atlas based automatic segmentation tools can be used to increase the efficiency of contour accuracy evaluation. This study aims to optimize technical parameters utilized in the tool by exploring the impact of library size and atlas number on the accuracy of cardiac contour evaluation. METHODS: Patient CT DICOMs from RTOG 0617 were used for this study. Five experienced physicians delineated the cardiac structures including pericardium, atria and ventricles following an atlas guideline...
June 2015: Medical Physics
https://www.readbyqxmd.com/read/26095784/ramucirumab-versus-placebo-as-second-line-treatment-in-patients-with-advanced-hepatocellular-carcinoma-following-first-line-therapy-with-sorafenib-reach-a-randomised-double-blind-multicentre-phase-3-trial
#18
RANDOMIZED CONTROLLED TRIAL
Andrew X Zhu, Joon Oh Park, Baek-Yeol Ryoo, Chia-Jui Yen, Ronnie Poon, Davide Pastorelli, Jean-Frederic Blanc, Hyun Cheol Chung, Ari D Baron, Tulio Eduardo Flesch Pfiffer, Takuji Okusaka, Katerina Kubackova, Jorg Trojan, Javier Sastre, Ian Chau, Shao-Chun Chang, Paolo B Abada, Ling Yang, Jonathan D Schwartz, Masatoshi Kudo
BACKGROUND: VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist. We aimed to assess the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma following first-line therapy with sorafenib. METHODS: In this randomised, placebo-controlled, double-blind, multicentre, phase 3 trial (REACH), patients were enrolled from 154 centres in 27 countries...
July 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26045340/necitumumab-plus-gemcitabine-and-cisplatin-versus-gemcitabine-and-cisplatin-alone-as-first-line-therapy-in-patients-with-stage-iv-squamous-non-small-cell-lung-cancer-squire-an-open-label-randomised-controlled-phase-3-trial
#19
RANDOMIZED CONTROLLED TRIAL
Nick Thatcher, Fred R Hirsch, Alexander V Luft, Aleksandra Szczesna, Tudor E Ciuleanu, Mircea Dediu, Rodryg Ramlau, Rinat K Galiulin, Beatrix Bálint, György Losonczy, Andrzej Kazarnowicz, Keunchil Park, Christian Schumann, Martin Reck, Henrik Depenbrock, Shivani Nanda, Anamarija Kruljac-Letunic, Raffael Kurek, Luis Paz-Ares, Mark A Socinski
BACKGROUND: Necitumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody. In this study, we aimed to compare treatment with necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone in patients with previously untreated stage IV squamous non-small-cell lung cancer. METHODS: We did this open-label, randomised phase 3 study at 184 investigative sites in 26 countries. Patients aged 18 years or older with histologically or cytologically confirmed stage IV squamous non-small-cell lung cancer, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and adequate organ function and who had not received previous chemotherapy for their disease were eligible for inclusion...
July 2015: Lancet Oncology
https://www.readbyqxmd.com/read/25748862/patients-use-normalisation-techniques-to-cope-with-the-quality-of-life-effects-of-anal-cancer
#20
Gitte Lee Mortensen, Lilli Lundby
INTRODUCTION: Anal cancer is a rare malignancy, but during the past three decades, its incidence has increased in both sexes. Approximately 90% of anal cancers are related to human papillomavirus infection. The primary treatment for anal cancer is radiotherapy or radio-chemotherapy. This quality of life (QoL) study aimed at obtaining in-depth knowledge about patients' experiences with anal cancer and its impact on their QoL. METHODS: A literature study identified topics for qualitative interviews with six anal cancer patients who had received oncological treatment and were without recurrent disease...
March 2015: Danish Medical Journal
keyword
keyword
59419
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"